Skip to content
Laurus Labs logo

Laurus Labs

LAURUSLABS NSE
₹2,294.60 −11.40 (−0.49%)
Market Cap
₹1,23,980 Cr
P/E
92.52
View as Markdown
MCP
Close 20 Nov 2026 ₹2,294.60 1Y +1,315.05 +134%
Start ₹979.55

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.80%
Debt to Equity
0.43
EPS (TTM)
₹24.80
Book Value
₹112.18
Market Cap
₹1,23,980 Cr
P/E (TTM)
92.52
P/B
20.45
ROE
18.30%
Dividend Yield
0.04%
EBITDA
₹1,833 Cr
52W High
₹2,488.00
52W Low
₹917.95
Day Range
₹2,286.80 – ₹2,320.00
Volume
8,79,357

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Laurus Labs peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
Laurus Labs (this company)
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Median 7 companies1,884.9041.441,23,9805.070.57%16.50%17.80%28,1392,855

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
66
Strong
Returns, margins, earnings quality 22% weight
Valuation
23
Poor
Cheap vs sector & own history 24% weight
Growth
70
Strong
Sales & profit trajectory 9% weight
Financial Health
48
Average
Solvency, leverage, coverage 9% weight
Momentum
95
Strong
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 19.0%

Weaknesses

4
  • Stock is trading at 20.5 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.4% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish568
OscillatorsBearish261
Moving AveragesStrong Bullish307

Key readings

RSI (14)
53.53
Neutral
MACD (12,26,9)
62.40
Bearish
SMA (50)
2,126.17
Bullish
SMA (200)
1,547.69
Bullish

As of

Analyst Rating

Based on 12 analysts
BUY50%

6 of 12 analysts rate Buy, 3 Hold, 3 Sell.

As of

BUY
6
50%
HOLD
3
25%
SELL
3
25%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+14.38%
5Y+7.19%
3Y+4.09%
1Y+22.67%
TTM+23.03%

Net profit

Net profit growth by window
10Y+20.84%
5Y−1.99%
3Y+3.92%
1Y+148.60%
TTM+95.31%

Operating cash flow

Operating cash flow growth by window
10Y+24.47%
5Y+17.25%
3Y+17.78%
1Y+169.77%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+5.84 pp
5Y−6.04 pp
3Y−0.15 pp
1Y+7.20 pp
TTM+6.98 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,905 Cr
Mar 2018₹2,056 Cr
Mar 2019₹2,292 Cr
Mar 2020₹2,832 Cr
Mar 2021₹4,814 Cr
Mar 2022₹4,936 Cr
Mar 2023₹6,041 Cr
Mar 2024₹5,041 Cr
Mar 2025₹5,554 Cr
Mar 2026₹6,813 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹190 Cr
Mar 2018₹168 Cr
Mar 2019₹94.00 Cr
Mar 2020₹255 Cr
Mar 2021₹984 Cr
Mar 2022₹832 Cr
Mar 2023₹793 Cr
Mar 2024₹162 Cr
Mar 2025₹358 Cr
Mar 2026₹890 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹692 Cr −9.4% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk high

Laurus Labs trades at ₹2,338 as of 2026-11-17 with a market cap of ₹1,26,325 crore and a trailing P/E of 94.27x. The stock has surged 117% over the past year, supported by a sharp TTM profit growth of 96%, but longer-term profit compounding over five years remains negative at -2%, highlighting the cyclical nature of recent earnings recovery.

Bull Case 8
  • TTM profit growth of 96% signals a strong earnings recovery, indicating a potential inflection in the business cycle
  • TTM sales growth of 23% shows meaningful top-line acceleration compared to the 3-year compounded sales growth of just 4%
  • 10-year compounded profit growth of 21% demonstrates a long track record of earnings expansion through cycles
  • ROE has improved to 16.38% currently and 18% last year, up from a 3-year average of 10%, reflecting improving capital efficiency
  • ROCE of 19.67% indicates healthy returns on total capital employed, suggesting productive deployment of both equity and debt
  • Debt-to-equity ratio of 0.46 is manageable for a capital-intensive healthcare company, providing financial flexibility for growth investments
  • 10-year compounded sales growth of 14% reflects a sustained ability to scale revenues over the long term
  • The company has maintained a healthy dividend payout ratio of 19.0%, returning capital to shareholders even through periods of earnings volatility
Bear Case 7
  • Trailing P/E of 94.27x is extremely elevated, demanding sustained high earnings growth to justify the valuation
  • Price-to-book ratio of 20.84x is exceptionally rich, meaning the stock trades at nearly 20 times its book value
  • 5-year compounded profit growth is negative at -2%, indicating that the recent TTM surge follows a prolonged earnings decline rather than steady compounding
  • 5-year compounded sales growth of only 7% is modest for a company commanding such premium valuation multiples
  • 3-year average ROE of only 10% suggests that the recent improvement to 16-18% may not be structurally sustainable
  • Dividend yield of just 0.05% offers negligible income return, placing nearly all return expectations on capital appreciation
  • There are indications the company might be capitalizing interest costs, which could overstate reported profitability and asset values

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

20h ago

TL;DR: Laurus Labs delivered a standout Q2 FY27 with 126% profit growth and 75% CDMO revenue surge, supported by margin expansion to 34.5% and rising FPI interest. However, the CEO selling 95% of his direct holding near the all-time high of ₹2,488 triggered a sharp 9% single-day correction and raised alignment concerns, despite core promoter holding via NSN Holdings (~23%) remaining intact. Valuations remain stretched at ~98x trailing PE. Near-term trajectory hinges on whether Q3 results sustain the CDMO momentum and whether management provides clarity on the promoter sales to restore market confidence.

Headwinds 3
  • Promoters sell ₹500cr near peak Nov 16

    CEO Satyanarayana Chava sold 14.85 lakh shares (95% of direct holding) and Leven Holdings sold 4.78 lakh shares on Nov 11 when the stock hit its record high of ₹2,488. Total promoter sale exceeded 20 lakh shares worth ~₹500 crore.

  • Stock crashes 9% on insider sale Nov 16

    Shares fell ~9% to ₹2,205 on Nov 16, the worst single-day drop in nearly two years, as delayed disclosure of the Nov 11 promoter sales hit the market in one shock.

  • Stretched valuation at ~98x PE Nov 16

    Trailing P/E ratio hovered around 98x, nearly 3x the industry average, leaving little room for negative surprises after a 130% one-year rally.

Positives 6
  • Record Q2 with 126% profit surge Nov 16

    Q2 FY27 consolidated net profit jumped 126% YoY to ₹441 crore on revenue of ₹2,206 crore (+33% YoY). EBITDA rose 78% to ₹762 crore with margins expanding 850bps to 34.5%.

  • CDMO revenue surges 75% Nov 16

    CDMO segment revenue grew 75% YoY to ₹904 crore in Q2 FY27, with small-molecule CDMO alone up 86% to ₹875 crore. Analysts forecast CDMO revenue to reach ₹7,160 crore by FY29E.

  • Pharma sector leader, up 112% YTD Nov 5

    Laurus Labs led the pharma sector with a 112% YTD gain as the pharma index rose 27%, significantly outperforming other sectors. The stock rallied 171% in nine months from its Feb low of ₹918.

Neutral 2
  • Investor conference participation Nov 10

    Laurus Labs confirmed participation in an annual investor conference in Mumbai on Nov 17, 2026, with no price-sensitive information to be shared.

  • Joint Company Secretary appointed Oct 29

    Kundan Kumar Jha appointed as Joint Company Secretary effective Nov 1, 2026, bringing over 23 years of corporate governance experience.

Quarterly Results

₹ Cr
LAURUSLABS quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,224
1,195
1,440
1,195
1,224
1,415
1,720
1,570
1,653
1,778
1,812
2,026
2,206
Expenses
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
1,299
1,388
1,456
Operating Profit
188
181
241
171
178
285
421
382
403
480
512
638
750
OPM %
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
32%
34%
Other Income
2
2
19
3
5
9
59
10
27
6
12
9
13
Interest
42
51
50
49
53
58
56
52
40
39
40
42
44
Depreciation
93
98
102
106
108
106
110
117
120
121
122
124
127
PBT
54
35
107
18
23
131
312
224
270
327
361
481
592
Tax %
27%
27%
30%
34%
22%
31%
25%
28%
28%
22%
22%
25%
26%
Net Profit
37
23
75
13
20
93
233
162
194
252
282
362
436
EPS (₹)
0.69
0.43
1.40
0.23
0.37
1.71
4.33
3.02
3.61
4.66
5.17
6.80
8.17
YoY Sales growth
−22
−23
4
1
0
18
19
31
35
26
5
29
33

Profit & Loss

₹ Cr
LAURUSLABS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,327
1,778
1,905
2,056
2,292
2,832
4,814
4,936
6,041
5,041
5,554
6,813
7,823
Expenses
1,126
1,415
1,497
1,642
1,935
2,266
3,262
3,512
4,448
4,261
4,499
5,028
5,442
Operating Profit
200
362
408
414
357
565
1,552
1,424
1,592
779
1,055
1,785
2,381
OPM %
15%
20%
21%
20%
16%
20%
32%
29%
26%
15%
19%
26%
30%
Other Income
34
4
32
29
16.15
5.92
23.66
14
6
26.34
75
47
40
Interest
106
111
100
80
88
90
68
102
165
183
216
171
166
Depreciation
62
86
106
125
164
187
205
251
324
385
430
480
494
PBT
67
169
234
237
120
294
1,301
1,084
1,109
236
484
1,182
1,761
Tax %
−2%
21%
19%
29%
22%
13%
24%
23%
28%
29%
27%
25%
—
Net Profit
68
134
190
168
94
255
984
832
793
162
358
890
1,332
EPS (₹)
1.38
2.71
3.60
3.16
1.76
4.77
18.33
15.40
14.67
2.98
6.64
16.46
24.80
Div. Payout %
0%
2%
8%
9%
17%
10%
11%
13%
14%
27%
18%
12%
—
Sales growth
14
34
7
8
11
24
70
3
22
−17
10
23
23

Balance Sheet

₹ Cr
LAURUSLABS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
16
16
106
106
106
107
107
107
108
108
108
108
108
Reserves
640
774
1,225
1,377
1,452
1,663
2,490
3,244
3,930
4,003
4,365
5,192
5,953
Borrowings
888
1,094
842
980
1,036
1,079
1,482
1,777
2,015
2,577
2,764
2,518
2,625
Other Liabilities
345
339
481
554
737
901
1,671
1,840
1,608
1,699
2,099
2,693
2,828
Total Liabilities
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
11,514
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,652
3,409
3,890
4,123
4,371
4,351
CWIP
110
70
143
163
110
67
362
813
551
423
458
773
1,282
Investments
7
7
3
3
3
3
3
31
50
124
233
309
310
Other Assets
970
1,126
1,277
1,369
1,589
1,953
3,214
3,472
3,651
3,950
4,521
5,058
5,570
Total Assets
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
11,514

Cash Flow

₹ Cr
LAURUSLABS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−65
182
332
342
298
347
733
911
994
666
602
1,624
Investing
−397
−312
−289
−384
−253
−221
−941
−914
−997
−822
−680
−1,086
Financing
486
103
−54
42
−45
−128
255
30
−27
250
39
−525
Net Cash Flow
24
−27
−10
1
0
−1
47
27
−30
93
−39
13
Free Cash Flow
−447
−144
55
−49
44
125
49
34
6
−10
61
560
CFO/EBITDA
−24
59
94
98
91
68
62
77
80
99
70
107

Ratios

LAURUSLABS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
78
91
109
101
113
102
99
100
96
120
132
115
Inventory Days
210
176
186
201
201
234
266
293
222
277
285
317
Days Payable
102
90
96
107
144
159
199
146
94
158
141
170
Cash Conversion Cycle
186
178
199
195
170
177
166
247
224
240
276
263
Working Capital Days
0
19
3
−11
6
15
43
43
59
42
43
58
ROCE %
14%
16%
16%
14%
8%
14%
40%
26%
23%
7%
9%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Laurus Labs insights

77 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • FIIs 30.84%
  • Promoters 27.47%
  • Public 20.03%
  • DIIs 11.86%
  • Others 9.81%

2.19% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Laurus Labs

What does Laurus Labs Ltd do?
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics.
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Laurus Labs Ltd trades as LAURUSLABS on the NSE and under code 540222 on the BSE.
Which sector does Laurus Labs Ltd belong to?
Laurus Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Laurus Labs Ltd?
Laurus Labs Ltd has a market capitalisation of ₹1,23,980 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Laurus Labs Ltd?
Laurus Labs Ltd trades at a PE ratio of 92.52 as of 20 Nov 2026, on earnings per share of ₹24.8, against a book value of ₹112.18 per share.
What is the 52-week high and low of Laurus Labs Ltd?
Over the last 52 weeks Laurus Labs Ltd has traded between ₹917.95 and ₹2,488 as of 20 Nov 2026.
Does Laurus Labs Ltd pay dividends?
Laurus Labs Ltd has a dividend yield of 0.04%.
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Laurus Labs Ltd reported a return on equity of 18.30%. Its debt-to-equity ratio is 0.43.

Company Information

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.

CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
Employees 6,167
Listed 19 Dec 2016
Face Value ₹2
Shares Outstanding 54,03,12,218

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LAURUSLABS.md for Laurus Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More